Scholarlink

<p>To evaluate the association between lymph node metastasis (LNM) and clinicopathological features/survival outcomes in oligometastatic prostate cancer (omPCa) patients undergoing cytoreductive radical prostatectomy (cRP) with pelvic lymph node dissection (LND). We retrospectively analyzed 57 omPCa patients undergoing cytoreductive radical prostatectomy (cRP) with LND between 2015 and 2022. Participants were stratified into lymph node-positive (N1, <i>n</i> = 16) and negative (N0, <i>n</i> = 41) groups based on postoperative pathology. Clinicopathological characteristics and survival outcomes were compared between groups. LNM-positive (pN1, <i>n</i> = 16) patients exhibited significantly higher baseline PSA (<i>p</i> = 0.026), Gleason scores (<i>p</i> = 0.013), and T-stage (<i>p</i> &lt; 0.001) than pN0 patients (<i>n</i> = 41). While PSA99 achievement rates were comparable (<i>p</i> = 0.852), pN1 patients had significantly lower rates of undetectable PSA (<i>p</i> &lt; 0.05), shorter median PSA progression-free survival (21 vs. 53 months, <i>p</i> &lt; 0.05), and shorter median CRPC-free survival (26 months vs. unreached, <i>p</i> &lt; 0.05). LNM in omPCa is associated with aggressive tumor biology and predicts inferior survival outcomes despite multimodal therapy. These findings highlight the critical need for improved preoperative nodal staging and intensified adjuvant strategies in pN1 omPCa patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lymph Node Metastasis Predicts Early Progression and Castration Resistance in Oligometastatic Prostate Cancer after Cytoreductive Radical Prostatectomy

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Jieping Hu,
  • Yuyang Yuan,
  • Jianbo Yang,
  • Xinchang Zou,
  • Yifan Tan,
  • Weilin Chen,
  • Xu Hu,
  • Weipeng Liu,
  • Bin Fu

摘要

To evaluate the association between lymph node metastasis (LNM) and clinicopathological features/survival outcomes in oligometastatic prostate cancer (omPCa) patients undergoing cytoreductive radical prostatectomy (cRP) with pelvic lymph node dissection (LND). We retrospectively analyzed 57 omPCa patients undergoing cytoreductive radical prostatectomy (cRP) with LND between 2015 and 2022. Participants were stratified into lymph node-positive (N1, n = 16) and negative (N0, n = 41) groups based on postoperative pathology. Clinicopathological characteristics and survival outcomes were compared between groups. LNM-positive (pN1, n = 16) patients exhibited significantly higher baseline PSA (p = 0.026), Gleason scores (p = 0.013), and T-stage (p < 0.001) than pN0 patients (n = 41). While PSA99 achievement rates were comparable (p = 0.852), pN1 patients had significantly lower rates of undetectable PSA (p < 0.05), shorter median PSA progression-free survival (21 vs. 53 months, p < 0.05), and shorter median CRPC-free survival (26 months vs. unreached, p < 0.05). LNM in omPCa is associated with aggressive tumor biology and predicts inferior survival outcomes despite multimodal therapy. These findings highlight the critical need for improved preoperative nodal staging and intensified adjuvant strategies in pN1 omPCa patients.